跳至主要内容
临床试验/EUCTR2004-000573-54-IT
EUCTR2004-000573-54-IT进行中(未招募)不适用

An Open-Label Study Examining the Long-Term Safety of Exenatide Given Twice Daily to Patients with Type 2 Diabetes Mellitus

ELI LILLY0 个研究点目标入组 500 人开始时间: 2005年4月14日最近更新:
适应症

试验速览

阶段
不适用
状态
进行中(未招募)
发起方
ELI LILLY
入组人数
500

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional clinical trial of medicinal product

入排标准

性别
All

入选标准

  • Are the trial subjects under 18? no
  • Number of subjects for this age range:
  • F.1.2 Adults (18-64 years) yes
  • F.1.2.1 Number of subjects for this age range
  • F.1.3 Elderly (>=65 years) no
  • F.1.3.1 Number of subjects for this age range

排除标准

  • 未提供

研究者

发起方
ELI LILLY

相似试验

尚未招募
3 期
An Open-Label Study Investigating Long-Term Safety and Tolerability of Nasalfent (Fentanyl Citrate Nasal Spray) in the Treatment of Breakthrough Cancer Pain (BTCP) in Subjects Taking Regular Opioid TherapyBreak ThroughCancer Pain10027656
NL-OMON30752I3Research36
进行中(未招募)
不适用
An Open-Label Study Investigating Long-Term Safety andTolerability of Nasalfent (Fentanyl Citrate Nasal Spray) in theTreatment of Breakthrough Cancer Pain (BTCP) in SubjectsTaking Regular Opioid Therapy - NDtrattamento del dolore oncologico episodico intenso (Breakthrough Cancer Pain, BTCP,) nei soggetti in terapia analgesica con oppioidi assunta regolarmenteMedDRA version: 6.1Level: PTClassification code 10058019
EUCTR2006-005403-34-ITARCHIMEDES500
招募中
3 期
ong-Term Safety Evaluation of Evinacumab in Patients Homozygous for Familial HypercholesterolemiaHomozygous familial hypercholesterolemia
JPRN-jRCT2051220184Makino Hisashi11
招募中
1 期
An Open-Label Study to Evaluate the Long-Term Safety, Tolerability and Efficacy of OMS906 in Patients with Paroxysmal Nocturnal Hemoglobinuria (PNH)Paroxysmal Nocturnal Hemoglobinuria (PNH)MedDRA version: 21.1Level: LLTClassification code: 10055629Term: Paroxysmal nocturnal hemoglobinuria Class: 10038359
CTIS2023-507413-10-00Omeros Corp.26
进行中(未招募)
1 期
Open-Label Study of Long-Term Safety and Efficacy of Lanadelumab forPrevention of Acute Attacks of Non-histaminergic Angioedema withNormal C1-Inhibitor
EUCTR2019-004823-20-DETakeda Development Center Americas (TDCA)75